Joint repair using mesenchymal stem cells

Patent metadata

Field	Value
Publication number	US-9814580-B2
Application number	US-201514687963-A
Country	US
Kind code	B2
Filing date	Apr 16, 2015
Priority date	Apr 25, 2000
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.

First claim

The invention claimed is:

1. A method of repairing damaged meniscal tissue in a joint of an animal with osteoarthritis, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, or juvenile arthritis, comprising:
administering directly to the joint via intra-articular injection a suspension comprising isolated allogeneic mesenchymal stem cells in an amount effective to repair damaged meniscal tissue in the joint of the animal, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, and
wherein the suspension is administered in the absence of a scaffold.

2. The method of claim 1 , wherein said mesenchymal stem cells differentiate into meniscal tissue.

3. The method of claim 1 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

4. The method of claim 1 , wherein said joint is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

5. The method of claim 1 , wherein the mesenchymal stem cells are present in the suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells and the mesenchymal stem cells are expanded in culture.

6. A method of repairing damaged meniscal tissue in a joint to reduce joint pain in a human, comprising:
administering via intra-articular injection a suspension comprising isolated allogeneic mesenchymal stem cells in an amount effective to reduce joint pain, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, and wherein the suspension is administered in the absence of a scaffold.

7. The method of claim 6 , wherein said mesenchymal stem cells regenerate meniscal tissue between opposing bone or osteochondral surfaces.

8. The method of claim 6 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

9. The method of claim 6 , wherein said joint is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

10. The method of claim 6 , wherein the mesenchymal stem cells are present in the suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells and the mesenchymal stem cells are expanded in culture.

11. A method of repairing damaged meniscal tissue in a joint to prevent osteoarthritis, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, or juvenile arthritis at a site damaged by meniscal injury in a human, comprising:
administering via intra-articular injection a suspension comprising isolated allogeneic mesenchymal stem cells in an amount effective to prevent osteoarthritis, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, or juvenile arthritis at the site, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, and wherein the suspension is administered in the absence of a scaffold.

12. The method of claim 11 , wherein said mesenchymal stem cells regenerate meniscal tissue between opposing bone or osteochondral surfaces.

13. The method of claim 11 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

14. The method of claim 11 , wherein said site is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

15. The method of claim 11 , wherein the mesenchymal stem cells are present in the suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells and the mesenchymal stem cells are expanded in culture.

16. A method of repairing damaged meniscal tissue in a joint to reduce osteophyte formation at a site damaged by meniscal injury in a human, comprising:
administering via intra-articular injection a suspension comprising isolated allogeneic mesenchymal stem cells in an amount effective to reduce osteophyte formation at the site, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, and wherein the suspension is administered in the absence of a scaffold.

17. A method of repairing damaged meniscal tissue in a joint of an animal with osteoarthritis, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, or juvenile arthritis, comprising:
injecting a suspension of isolated allogeneic mesenchymal stem cells directly to the joint via intra-articular injection
wherein the allogeneic mesenchymal stern cells are in an amount effective to repair damaged meniscal tissue in the joint of the animal, and wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue.

18. The method of claim 17 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

19. The method of claim 17 , wherein said site is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

20. The method of claim 17 , wherein the mesenchymal stem cells are present in the suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells and the mesenchymal stem cells are expanded in culture.

21. The method of claim 1 , wherein the animal is a human.

22. The method of claim 17 , wherein the animal is a human.

Assignees

• Mesoblast Int Sarl

Inventors

• Barry Francis P
• Murphy J Mary
• Deans Robert
• Fink David J
• Moseley Annemarie

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P19/04

  for non-specific disorders of the connective tissue · CPC title